Stockreport

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the ...

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF ECUR-506 is the first in vivo gene insertion program authorized for clinical investigation in infants in the U.S. BUSINESS WIRE iECURE , Inc. , a gene editing company [Read more]